A L ISA M ACHA L EK /N IG M S
GOVER NMENT & POL ICY
spent on grants—that’s been true since it was founded. Today, NIGMS spends about 60% of its budget on research proj ect grants, 20% on grants to centers, and about 8% on training grants. The remainder goes to other research, including support for minority biomedical researchers, as well as to R&D contracts, and research management and support. HOME BASE
The Natcher Building on the NIH campus in Bethesda, Md., is home to NIGMS.
CHEMISTRY HAS ALWAYS been im
NIGMS TURNS 50 One of NIH’s leading institutes continues to be a big supporter of BASIC SCIENCE BRITT E. ERICKSON, C&EN WASHINGTON
CONVINCING LAWMAKERS of the im
portance of basic science can be a hard sell, but officials at the National Institutes of Health’s National Institute of General Medical Sciences (NIGMS) have excelled at it for the past 50 years. Authorized by Congress in 1962 to support research and training in general or basic biomedical sciences, NIGMS is one of the largest insti tutes in terms of budget at NIH. From the beginning, NIGMS has sup ported fundamental research on how life works at the most basic level. Numerous significant medical breakthroughs have resulted from that research, including new ways to detect, treat, and prevent disease. In the late 1960s and early ’70s, the insti tute funded the basic science on restriction enzymes that led to recombinant DNA technology and genetic engineering. More recently, NIGMS has supported studies that catalyzed the fields of pharmaco genomics, protein structure analysis, cel lular imaging, computational biology, stem cell biology, and RNA biology. “NIGMS is the foundation on which everything else at NIH has been built and will be in the future,” NIH Director Francis S. Collins said last spring at an event on Capitol Hill to honor the 50th anniversary of NIGMS. “If you want to see that next breakthrough in Alzheimer’s, Parkinson’s, diabetes, or cancer, you have to be sure you are investing in the basic science that
teaches us those fundamentals upon which we can build that future.” In addition to supporting basic research, NIGMS is known for its efforts in prepar ing the next generation of biomedical scientists through various training grants and fellowships. The institute also has a reputation for promoting diversity in the biomedical workforce and for encouraging interdisciplinary research. NIGMS has grown from 114 employees and a budget of about $110 million in 1963, to 165 employees and a budget of about $2.4 billion today. Most of its money is
NIGMS AT A GLANCE Fiscal 2012 budget: $2.4 billion Percent of NIH grants supported by NIGMS: 11% Number of grants supported by NIGMS at any given time: ~4,700 Number of full-time employees: 165 Number of Nobel Prize-winning scientists funded: 74 Average amount of an R01 research grant in 2012: $343,847 Average amount of an R01 research grant in 1962: $22,810 NOTE: All dollar amounts in actual dollars. R01 = standard NIH-supported research grant. SOURCE: NIGMS
WWW.CEN-ONLIN E .ORG
20
AUGUST 20, 20 1 2
portant area of research for NIGMS. The institute has funded the work of 36 Nobel Prize-winning scientists in chemistry. “We realize that chemistry is integral to everything else we do,” says NIGMS Act ing Director Judith H. Greenberg. NIGMS funds more chemistry-related research than any of NIH’s other centers or insti tutes, but it is hard to get a handle on ex actly how much because the lines between chemistry and other sciences are often blurred, Greenberg notes. “We do know that we are spending prob ably as much on chemistry research as the National Science Foundation,” Greenberg tells C&EN. “We are a big player.” One area in particular that receives a lot of support from NIGMS is synthetic organic chemistry, notes Michael E. Rog ers, director of the Division of Pharmacol ogy, Physiology & Biological Chemistry at NIGMS. The institute also supports re search on metals in biology or bioinorganic chemistry, chemical biology, bioorganic chemistry, and medicinal chemistry. A big area of interest to NIGMS right now is glycomics—the comprehensive study of carbohydrates, Rogers says. NIGMS is also interested in chemistry as sociated with enzymes and enzyme mecha nisms, he notes. Through its Division of Cell Biology & Biophysics, NIGMS also supports a sub stantial amount of analytical chemistry, including work in nuclear magnetic reso nance spectroscopy, mass spectrometry, and the development of imaging probe re agents, Rogers says.“That support has been crucial to the development and application of those technologies,” he points out. One of the reasons NIGMS is such a big supporter of chemistry has a lot to do with Ruth L. Kirschstein, who directed the insti tute from 1974 to 1993. “When I first came to NIH in 1980, there was some discussion
of whether NIH should be supporting chemistry in a major way,” Rogers recalls. “Ruth took a strong stance that chemistry is an enabling science for health research and that it should be supported.” Kirschstein was the first woman to be come director of an NIH institute. She also served longer than any other NIGMS direc tor to date, and she is credited with shaping the current direction of the institute. “She really put her stamp on the institute in many ways,” Greenberg says. That stamp included a strong emphasis on investigator-initiated research and a commitment to research training, Green berg notes. Under Kirschstein’s leadership, NIGMS awarded training grants to institu tions rather than individuals in areas such as genetics, cell biology, bioengineering,
charm Congress. Kirschstein was well aware of who held the purse strings for NIH, and she got to know those lawmakers and their staffers. “She could even talk to them about their relatives,” Rogers re marks. During her directorship at NIGMS, the institute’s budget quadrupled. Beyond those profound influences, Kirschstein also set the culture for the in
IN CHARGE Seven directors have led NIGMS over its five-decade existence: ◾◾ Clinton C. Powell, 1962–64 ◾◾ Frederick L. Stone, 1964–70 ◾◾ DeWitt Stetten Jr., 1970–74 ◾◾ Ruth L. Kirschstein, 1974–93 ◾◾ Marvin Cassman, 1993–2002a ◾◾ Judith H. Greenberg (acting), 2002–03 ◾◾ Jeremy M. Berg, 2003–11 ◾◾ Judith H. Greenberg (acting), 2011– present a Cassman served as acting director from 1993 to 1996.
and pharmacology. NIGMS also estab lished an institutional training program at the chemistry-biology interface. The rationale for creating the chemistrybiology interface program was to make chemistry departments around the country feel included in NIGMS’s training efforts, Rogers says. “We wanted to make it very clear that they are part of our community.” Kirschstein was ahead of her time with respect to increasing the diversity of the biomedical workforce. She was in charge when NIGMS inherited a program aimed at supporting minority biomedical research ers from another NIH division in 1989, and she spearheaded the establishment of the Minority Opportunities in Research (MORE) Division at NIGMS in 1991 to in crease minority particpation in biomedical research and teaching. She was also known for her ability to WWW.CEN-ONLIN E .ORG
21
AUGUST 20, 20 1 2
stitute, Greenberg stresses. She hired top scientists and instilled a strong sense of mission in them even after she left NIGMS to become deputy director of NIH. “We work together for the benefit of science,” Greenberg says. “I am happy to say, that culture has lasted all of these years.” Another past director who had a long-lasting impact on the institute is
GOVER NMENT & POL ICY
Kirschstein’s predecessor, beginning to flatten and BUDGET SHARE Investigator-initiated research grants remain DeWitt Stetten Jr. When “there was a mixture of the primary focus of NIGMS. NIGMS was established, hope and anxiety,” recalls it invested more in ap Jeremy M. Berg, a chemist plied than basic research. who directed NIGMS from Initially, programs were 2003 to 2011. “There were established in clinically re attempts to try to prepare lated areas such as anesthe for the end of the doubling, siology, trauma, and burn and there was a lot of con research, and training was cern that things needed to focused on bridging the gap be managed carefully so between basic science and the best research could still clinical research. be done.” Stetten changed that. Shortly after Berg ar During his 1970–74 tenure rived at NIGMS, then-NIH NOTE: Grants include all research project grants but not centers or training grants. as director, NIGMS began director Elias A. Zerhouni NIGMS = National Institute of General Medical Sciences. SOURCE: National Institutes of Health investing more in basic launched an NIH-wide research through its genet initiative called the NIH ics program and a program on cell biology. in pharmacogenetics, the Protein Structure Roadmap for Medical Research to bring The institute continued that trend under Initiative, and a program focused on the NIH’s 27 institutes and centers together to Kirschstein’s leadership. modeling of infectious diseases, as well as work on common projects. NIGMS was in several other initiatives, Greenberg notes. volved in several NIH Roadmap projects. NIGMS, LIKE THE REST of NIH, experi The institute also began large collabora One of the efforts involved development enced a period of tremendous growth from tive grants called glue grants to encourage of molecular imaging probes. “We tried 1998 to 2002. During that time, the budgets interdisciplinary research, and it increased to build partnerships between chemists, of both NIH and NIGMS doubled. With the funding for grants awarded to centers. physicists, engineers, and cell biologists additional funds, NIGMS started a program But by 2003 the NIGMS budget was to push imaging probe technology to the
WWW.CEN-ONLIN E .ORG
22
AUGUST 20, 20 1 2
point where we could perform real-time imaging of individual molecules in live cells,” Berg says. “That work has contin ued, and the goal is now becoming closer and closer to being a reality.” NIGMS also played a key role in advanc ing the field of structural biology. “The focus was entirely on membrane proteins,” Berg recalls. “A lot of structural biology was moving quite well under its own power, but work on membrane proteins was an area that wasn’t as strong as everybody had been hoping.” Huge progress has been made in mem brane structural biology over the past 10 years as a result of efforts by NIGMS, Berg stresses. Many structures and mechanisms are now understood, he says. IN THE YEARS to come, NIGMS expects
to continue supporting basic biomedical research. Two areas that look particularly exciting are the dynamics of microbial-host interactions and bioinformatics and com putational biology, Greenberg points out. Like all government agencies, however, NIGMS faces an uncertain future in terms of its budget. It also faces uncertainty with respect to its future leadership. The institute has been without a permanent director since Berg left in July 2011 to take a position at the University of Pittsburgh (C&EN, June 20, 2011, page 28). NIGMS is also under pressure to move in the direction of translational research— to turn previous discoveries into treat ments and cures that have a direct impact on human health. Although much progress has been made in biomedical research over the past 50 years, “it is easy to lose sight of how little we actually understand,” Berg warns. “Continuing to invest in basic, curiositydriven research has been the strength of NIGMS over its history, and it continues to be important,” Berg says. “I think NIGMS needs to continue to articulate and sup port basic research in areas that are off the beaten track, while at the same time trying to bridge between what is known and areas of translation.” NIGMS is commemorating its 50th an niversary by holding various events this year, including a special symposium on the NIH campus in Bethesda, Md., in October. It also plans to showcase some of the work it has funded at various scientific meetings, including the American Chemical Society national meeting being held this week in Philadelphia. ◾ WWW.CEN-ONLIN E .ORG
23
AUGUST 20, 20 1 2
